^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD93 underexpression

    i
    Other names: CD93, CD93 Molecule, C1qR(P), CDw93, CD93 Antigen, DJ737E23.1, C1qRP, ECSM3, C1QR1, MXRA4, Complement Component 1 Q Subcomponent Receptor 1, Matrix-Remodeling-Associated Protein 4, Complement Component C1q Receptor, Matrix-Remodelling Associated 4, C1q/MBL/SPA Recepto, C1qR, Complement Component 1, Q Subcomponent, Receptor 1, C1q Receptor 1, C1qRp
    Entrez ID:
    22918
    2years
    The analysis of multiple omics and examination of pathological images revealed the prognostic and therapeutic significances of CD93 in lung squamous cell carcinoma. (PubMed, Life Sci)
    Immunohistochemistry validated the significance of CD93 in LUSC. CD93 emerges as a biomarker signaling unfavorable prognosis and influencing therapeutic outcomes, suggesting a potential LUSC treatment avenue.
    Journal • IO biomarker
    |
    CD93 (CD93 Molecule)
    |
    CD93 underexpression